芳香化酶抑制剂相关关节痛研究进展

doi:10.3969/j.issn.1006-9771.2019.07.013

摘要/Abstract

摘要： 雌激素缺乏、炎性反应、代谢紊乱等被认为是导致乳腺癌患者发生芳香化酶抑制剂(AIs)相关关节痛的可能机制。运动和其他手段(维生素D、Omega-3脂肪酸、针灸等)对改善AIs相关关节痛均有积极效果。运动可能通过直接或间接效应影响其相关发病机制而发挥作用，但结果尚存在一定争议。

关键词: 乳腺癌, 芳香化酶抑制剂, 关节痛, 运动, 综述

Abstract: Estrogen deficiency, inflammatory reactions, metabolic disorders, etc., are considered to be possible mechanisms leading to arthralgias (or joint pain) associated with aromatase inhibitors (AIs) in breast cancer patients. The use of exercise and other non-pharmacological means (such as vitamin D, Omega-3 fatty acids, acupuncture, etc.) may relieve AIs-related arthralgia, and exercise may play a direct or indirect role to deal with the related pathogenesis. But the results of the studies are still controversial.

Key words: breast cancer, aromatase inhibitors, arthralgia, exercise, review

中图分类号:

R737.9

钟救根, 侯晓晖, 兰号. 芳香化酶抑制剂相关关节痛研究进展[J]. 《中国康复理论与实践》, 2019, 25(7): 805-812.

ZHONG Jiu-gen, HOU Xiao-hui, LAN Hao. Advance in Aromatase Inhibitor Related Arthralgias (review)[J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2019, 25(7): 805-812.

参考文献

1 DowsettM, CuzickJ, IngleJ, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen [J]. J Clin Oncol, 2010, 28(3): 509-518.
2 CoombesR C, KilburnL S, SnowdonC F, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial [J]. Lancet, 2007, 369(9561): 559-570.
3 NiravathP. Aromatase inhibitor-induced arthralgia: a review [J]. Ann Oncol, 2013, 24(6): 1443-1449.
4 ChimK, XieS X, StrickerC T, et al. Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors [J]. BMC Cancer, 2013, 13: 401.
5 BoonstraA, van ZadelhoffJ, Timmer-BonteA, et al. Arthralgia during aromatase inhibitor treatment in early breast cancer patients: prevalence, impact, and recognition by healthcare providers [J]. Cancer Nurs, 2013, 36(1): 52-59.
6 LopezC, CharlesC, RoubyP, et al. Relations between arthralgia and fear of recurrence: results of a cross-sectional study of breast cancer patients treated with adjuvant aromatase inhibitors therapy [J]. Support Care Cancer, 2015, 23(12): 3581-3588.
7 PetrelliF, CoinuA, CabidduM, et al. Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials [J]. Breast Cancer Res Treat, 2013, 140(2): 233-240.
8 MaoJ J, StrickerC, BrunerD, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors [J]. Cancer, 2009, 115(16): 3631-3639.
9 YagataH, OhtsuH, KomoikeY, et al. Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole [J]. Support Care Cancer, 2016, 24(2): 683-689.
10 CrewK D, GreenleeH, CapodiceJ, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer [J]. J Clin Oncol, 2007, 25(25): 3877-3883.
11 BeckweeD, LeysenL, MeuwisK, et al. Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis [J]. Support Care Cancer, 2017, 25(5): 1673-1686.
12 LombardJ M, ZdenkowskiN, WellsK, et al. Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options [J]. Support Care Cancer, 2016, 24(5): 2139-2146.
13 GalantinoM L, CallensM L, CardenaG J, et al. Tai chi for well-being of breast cancer survivors with aromatase inhibitor-associated arthralgias: a feasibility study [J]. Altern Ther Health Med, 2013, 19(6): 38-44.
14 BorrieA E, RoseR V, ChoiY H, et al. Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer [J]. Breast Cancer Res Treat, 2018, 172(2): 371-379.
15 Winters-StoneK M, SchwartzA L, HayesS C, et al. A prospective model of care for breast cancer rehabilitation: bone health and arthralgias [J]. Cancer, 2012, 118(8 Suppl): 2288-2299.
16 CastelL D, WallstonK A, SavilleB R, et al. Validity and reliability of the Patient-Reported Arthralgia Inventory: validation of a newly-developed survey instrument to measure arthralgia [J]. Patient Relat Outcome Meas, 2015, 6: 205-214.
17 LiY, ZhangZ, CuiF, et al. Traditional Chinese Medicine Bionic Tiger Bone Powder for the treatment of AI-associated musculoskeletal symptoms [J]. Evid Based Complement Alternat Med, 2017, 2017: 2478565.
18 AndersenC, RorthM, EjlertsenB, et al. Exercise despite pain－breast cancer patient experiences of muscle and joint pain during adjuvant chemotherapy and concurrent participation in an exercise intervention [J]. Eur J Cancer Care (Engl), 2014, 23(5): 653-667.
19 IrwinM L, CartmelB, GrossC P, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors [J]. J Clin Oncol, 2015, 33(10): 1104-1111.
20 NyropK A, CallahanL F, RiniC, et al. Adaptation of an evidence-based arthritis program for breast cancer survivors on aromatase inhibitor therapy who experience joint pain [J]. Prev Chronic Dis, 2015, 12: E91.
21 MullerS T, KeilerA M, KrakerK, et al. Influence of estrogen on individual exercise motivation and bone protection in ovariectomized rats [J]. Lab Anim, 2018, 52(5): 479-489.
22 ShevdeN K, BendixenA C, DiengerK M, et al. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression [J]. PNAS, 2000, 97(14): 7829-7834.
23 KousteniS, BellidoT, PlotkinL I, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity [J]. Cell, 2001, 104(5): 719-730.
24 Crusode de SouzaM, Sasso-CerriE, CerriP S. Immunohistochemical detection of estrogen receptor beta in alveolar bone cells of estradiol-treated female rats: possible direct action of estrogen on osteoclast life span [J]. J Anat, 2009, 215(6): 673-681.
25 RiggsB L, SMelton L J 3rdKhosla. Sex steroids and the construction and conservation of the adult skeleton [J]. Endocr Rev, 2002, 23(3): 279-302.
26 KarsdalM A, Bay-JensenA C, HenriksenK, et al. The pathogenesis of osteoarthritis involves bone, cartilage and synovial inflammation: may estrogen be a magic bullet? [J]. Menopause Int, 2012, 18(4): 139-146.
27 HernandezJ L, GarcesC M, SumilleraM, et al. Aromatase expression in osteoarthritic and osteoporotic bone [J]. Arthritis Rheum, 2008, 58(6): 1696-1700.
28 PerezE A, JosseR G, PritchardK I, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17 [J]. J Clin Oncol, 2006, 24(22): 3629-3635.
29 ColemanR E, BanksL M, GirgisS I, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study [J]. Lancet Oncol, 2007, 8(2): 119-127.
30 RachnerT D, ColemanR, HadjiP, et al. Bone health during endocrine therapy for cancer [J]. Lancet Diabetes Endocrinol, 2018, 6(11): 901-910.
31 O'NeillT W, FelsonD T. Mechanisms of osteoarthritis (OA) pain [J]. Curr Osteoporos Rep, 2018, 16(5): 611-616.
32 DizdarO, OzcakarL, MalasF U, et al. Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia [J]. J Clin Oncol, 2009, 27(30): 4955-4960.
33 MoralesL, PansS, ParidaensR, et al. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging [J]. Breast Cancer Res Treat, 2007, 104(1): 87-91.
34 YounusJ K L. Management of aromatase inhibitor-induced arthralgia [J]. Curr Oncol, 2010, 17(1): 87-90.
35 KhoslaS. Update on estrogens and the skeleton [J]. J Clin Endocrinol Metab, 2010, 95(8): 3569-3577.
36 de BoerM C, WornerE A, VerlaanD, et al. The mechanisms and effects of physical activity on breast cancer [J]. Clin Breast Cancer, 2017, 17(4): 272-278.
37 PudkasamS, TangalakisK, ChinlumprasertN, et al. Breast cancer and exercise: the role of adiposity and immune markers [J]. Maturitas, 2017, 105: 16-22.
38 BaumlJ, ChenL, ChenJ, et al. Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia? [J]. Breast Cancer Res, 2015, 17: 89.
39 GunterM J, HooverD R, YuH, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women [J]. J Natl Cancer Inst, 2009, 101(1): 48-60.
40 IrwinM L, VarmaK, Alvarez-ReevesM, et al. Randomized controlled trial of aerobic exercise on insulin and insulin-like growth factors in breast cancer survivors: the Yale Exercise and Survivorship study [J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(1): 306-313.
41 LannD, LeRoithD. The role of endocrine insulin-like growth factor-I and insulin in breast cancer [J]. J Mammary Gland Biol Neoplasia, 2008, 13(4): 371-379.
42 LintermansA, VanderschuerenD, VerhaegheJ, et al. Arthralgia induced by endocrine treatment for breast cancer: a prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens [J]. Eur J Cancer, 2014, 50(17): 2925-2931.
43 SestakI, CuzickJ, SapunarF, et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis [J]. Lancet Oncol, 2008, 9(9): 866-872.
44 MaoJ J, SuH I, FengR, et al. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors [J]. Breast Cancer Res, 2011, 13(1): R8.
45 WangJ, LuK, SongY, et al. RANKL and OPG polymorphisms are associated with aromatase inhibitor-related musculoskeletal adverse events in Chinese Han breast cancer patients [J]. PLoS One, 2015, 10(7): e0133964.
46 RastelliA L, TaylorM E, GaoF, et al. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial [J]. Breast Cancer Res Treat, 2011, 129(1): 107-116.
47 Prieto-AlhambraD, JavaidM K, ServitjaS, et al. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study [J]. Breast Cancer Res Treat, 2011, 125(3): 869-878.
48 SchaibleHG. Spinal mechanisms contributing to joint pain [J]. Novartis Found Symp, 2004, 260: 4-22.
49 ColemanR E, BoltenW W, LansdownM, et al. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations [J]. Cancer Treat Rev, 2008, 34(3): 275-282.
50 YangG S, KimH J, GriffithK A, et al. Interventions for the treatment of aromatase inhibitor-associated arthralgia in breast cancer survivors: a systematic review and meta-analysis [J]. Cancer Nurs, 2017, 40(4): E26-E41.
51 HershmanD L, LoprinziC, SchneiderB P. Symptoms: aromatase inhibitor induced arthralgias [J]. Adv Exp Med Biol, 2015, 862: 89-100.
52 KimT H, KangJ W, LeeT H. Therapeutic options for aromatase inhibitor-associated arthralgia in breast cancer survivors: a systematic review of systematic reviews, evidence mapping, and network meta-analysis [J]. Maturitas, 2018, 118: 29-37.
53 CrewK D, ShaneE, CremersS, et al. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy [J]. J Clin Oncol, 2009, 27(13): 2151-2156.
54 KhanQ J, ReddyP S, KimlerB F, et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer [J]. Breast Cancer Res Treat, 2010, 119(1): 111-118.
55 GoldbergR J, KatzJ. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain [J]. Pain, 2007, 129(1-2): 210-223.
56 HershmanD L, UngerJ M, CrewK D, et al. Randomized multicenter placebo-controlled trial of omega-3 fatty acids for the control of aromatase inhibitor-induced musculoskeletal pain: SWOG S0927 [J]. J Clin Oncol, 2015, 33(17): 1910-1917.
57 ZhangS, Liang FHuX. Reply to M. Di Maio and F. Perrone [J]. J Clin Oncol, 2015, 33(36): 4310-4311.
58 ShenS, UngerJ M, CrewK D, et al. Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927) [J]. Breast Cancer Res Treat, 2018, 172(3): 603-610.
59 LustbergM B, OrchardT S, ReinboltR, et al. Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain [J]. Breast Cancer Res Treat, 2018, 167(3): 709-718.
60 CalderP C. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases [J]. Am J Clin Nutr, 2006, 83(6 Suppl): 1505S-1519S.
61 ChenL, LinC C, HuangT W, et al. Effect of acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancer: a meta-analysis of randomized controlled trials [J]. Breast, 2017, 33: 132-138.
62 HershmanD L, UngerJ M, GreenleeH, et al. Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial [J]. JAMA, 2018, 320(2): 167-176.
63 ChienT J, LiuC Y, ChangY F, et al. Acupuncture for treating aromatase inhibitor-related arthralgia in breast cancer: a systematic review and meta-analysis [J]. J Altern Complement Med, 2015, 21(5): 251-260.
64 BaoT, CaiL, GilesJ T, et al. A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors [J]. Breast Cancer Res Treat, 2013, 138(1): 167-174.
65 MaoJ J, XieS X, FarrarJ T, et al. A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use [J]. Eur J Cancer, 2014, 50(2): 267-276.
66 OhB, KimbleB, CostaD S, et al. Acupuncture for treatment of arthralgia secondary to aromatase inhibitor therapy in women with early breast cancer: pilot study [J]. Acupunct Med, 2013, 31(3): 264-271.
67 PlaydonM C, BrackenM B, SanftT B, et al. Weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis [J]. J Natl Cancer Inst, 2015, 107(12): djv275.
68 SilvaD A S, TremblayM S, SouzaM F M, et al. Mortality and years of life lost due to breast cancer attributable to physical inactivity in the Brazilian female population (1990-2015) [J]. Sci Rep, 2018, 8(1): 11141.
69 VolaklisK A, Halle MTokmakidisS P. Exercise in the prevention and rehabilitation of breast cancer [J]. Wien Klin Wochenschr, 2013, 125(11-12): 297-301.
70 AdraskelaK, VeisakiE, KoutsilierisM, et al. Physical exercise positively influences breast cancer evolution [J]. Clin Breast Cancer, 2017, 17(6): 408-417.
71 WirtzP, BaumannF T. Physical activity, exercise and breast cancer－what is the evidence for rehabilitation, aftercare, and survival? A review [J]. Breast Care (Basel), 2018, 13(2): 93-101.
72 ThomasG A, CartmelB, HarriganM, et al. The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors [J]. Obesity (Silver Spring), 2017, 25(2): 346-351.
73 IrwinM L, Alvarez-ReevesM, CadmusL, et al. Exercise improves body fat, lean mass, and bone mass in breast cancer survivors [J]. Obesity (Silver Spring), 2009, 17(8): 1534-1541.
74 ShinW K, SongS, JungS Y, et al. The association between physical activity and health-related quality of life among breast cancer survivors [J]. Health Qual Life Outcomes, 2017, 15(1): 132.
75 IrwinM L, McTiernanA, MansonJ E, et al. Physical activity and survival in postmenopausal women with breast cancer: results from the women's health initiative [J]. Cancer Prev Res (Phila), 2011, 4(4): 522-529.
76 RunowiczC D, LeachC R, HenryN L, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline [J]. J Clin Oncol, 2016, 34(6): 611-635.
77 AremH, SorkinM, CartmelB, et al. Exercise adherence in a randomized trial of exercise on aromatase inhibitor arthralgias in breast cancer survivors: the Hormones and Physical Exercise (HOPE) study [J]. J Cancer Surviv, 2016, 10(4): 654-662.
78 FieldsJ, RichardsonA, HopkinsonJ, et al. Nordic walking as an exercise intervention to reduce pain in women with aromatase inhibitor-associated arthralgia: a feasibility study [J]. J Pain Symptom Manage, 2016, 52(4): 548-559.
79 NyropK A, CallahanL F, ClevelandR J, et al. Randomized controlled trial of a home-based walking program to reduce moderate to severe aromatase inhibitor-associated arthralgia in breast cancer survivors [J]. Oncologist, 2017, 22(10): 1238-1249.
80 PepponeL J, JanelsinsM C, KamenC, et al. The effect of YOCAS(c)(R) yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy [J]. Breast Cancer Res Treat, 2015, 150(3): 597-604.
81 GalantinoM L, DesaiK, GreeneL, et al. Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor-associated arthralgias [J]. Integr Cancer Ther, 2012, 11(4): 313-320.
82 JacobsenP B, MuchnickS, MarcusS, et al. Pilot study of Iyengar yoga for management of aromatase inhibitor-associated arthralgia in women with breast cancer [J]. Psychooncology, 2015, 24(11): 1578-1580.
83 WangC, SchmidC H, IversenM D, et al. Comparative effectiveness of Tai Chi versus physical therapy for knee osteoarthritis: a randomized trial [J]. Ann Intern Med, 2016, 165(2): 77-86.
84 KuboM, OnishiH, KurokiS, et al. Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer [J]. Anticancer Res, 2012, 32(6): 2331-2336.
85 UhlenbruckG, van LeendertR, SchneiderB, et al. Reduced side-effects of adjuvant hormone therapy in breast cancer patients by complementary medicine [J]. In Vivo, 2010, 24(5): 799-802.
86 GreenleeH, CrewK D, ShaoT, et al. Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer [J]. Support Care Cancer, 2013, 21(4): 1077-1087.
87 ZhangQ, TangD, ZhaoH. Immunological therapies can relieve aromatase inhibitor-related joint symptoms in breast cancer survivors [J]. Am J Clin Oncol, 2010, 33(6): 557-560.
88 ChinoA, OkamotoH, HirasakiY, et al. A case of aromatase inhibitor (anastrozole)-induced side-effects successfully treated with Kampo medicines [J]. J Altern Complement Med, 2011, 17(11): 1075-1077.
89 YehC H, LinW C, Kwai-Ping SuenL, et al. Auricular point acupressure to manage aromatase inhibitor-induced arthralgia in postmenopausal breast cancer survivors: a pilot study [J]. Oncol Nurs Forum, 2017, 44(4): 476-487.
90 KarpJ C, SanchezC, GuilbertP, et al. Treatment with Ruta graveolens 5CH and Rhus toxicodendron 9CH may reduce joint pain and stiffness linked to aromatase inhibitors in women with early breast cancer: results of a pilot observational study [J]. Homeopathy, 2016, 105(4): 299-308.
91 ChanA, De BoerR, GanA, et al. Randomized phase II placebo-controlled study to evaluate the efficacy of topical pure emu oil for joint pain related to adjuvant aromatase inhibitor use in postmenopausal women with early breast cancer: JUST (Joints Under Study) [J]. Support Care Cancer, 2017, 25(12): 3785-3791.
92 VerkasaloP K, ThomasH V, ApplebyP N, et al. Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women (United Kingdom) [J]. Cancer Causes Control, 2001, 12(1): 47-59.
93 EmausA, VeierodM B, FurbergA S, et al. Physical activity, heart rate, metabolic profile, and estradiol in premenopausal women [J]. Med Sci Sports Exerc, 2008, 40(6): 1022-1030.
94 McTiernanA, WuL, ChenC, et al. Relation of BMI and physical activity to sex hormones in postmenopausal women [J]. Obesity (Silver Spring), 2006, 14(9): 1662-1677.
95 OhH, AremH, MatthewsC E, et al. Sitting, physical activity, and serum oestrogen metabolism in postmenopausal women: the Women's Health Initiative Observational Study [J]. Br J Cancer, 2017, 117(7): 1070-1078.
96 ZimmerP, BaumannF T, ObersteM, et al. Influence of personalized exercise recommendations during rehabilitation on the sustainability of objectively measured physical activity levels, fatigue, and fatigue-related biomarkers in patients with breast cancer [J]. Integr Cancer Ther, 2018, 17(2): 306-311.
97 IdornM, HojmanP. Exercise-dependent regulation of NK cells in cancer protection [J]. Trends Mol Med, 2016, 22(7): 565-577.
98 PedersenL, IdornM, OlofssonG H, et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution [J]. Cell Metab, 2016, 23(3): 554-562.
99 JonesS B, ThomasG A, HesselsweetS D, et al. Effect of exercise on markers of inflammation in breast cancer survivors: the Yale exercise and survivorship study [J]. Cancer Prev Res (Phila), 2013, 6(2): 109-118.
100 XuH, BarnesG T, YangQ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance [J]. J Clin Invest, 2003, 112(12): 1821-1830.
101 Ballard-BarbashR, FriedenreichC M, CourneyaK S, et al. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review [J]. J Natl Cancer Inst, 2012, 104(11): 815-840.
102 FaireyA S, CourneyaK S, FieldC J, et al. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial [J]. Cancer Epidemiol Biomarkers Prev, 2003, 12(8): 721-727.
103 BaileyC A, Brooke-WavellK. Exercise for optimising peak bone mass in women [J]. Proc Nutr Soc, 2008, 67(1): 9-18.
104 SaundersM M, TaylorA F, DuC, et al. Mechanical stimulation effects on functional end effectors in osteoblastic MG-63 cells [J]. J Biomech, 2006, 39(8): 1419-1427.
105 LintermansA, van AstenK, JongenL, et al. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients [J]. Eur J Cancer, 2016, 56: 31-36.
106 KapczukK, Sowinska-PrzepieraE, FriebeZ. Osteoprotegerin/RANKL/RANK system and postmenopausal osteoporosis. The possible therapeutic aspects [J]. Ginekol Pol, 2003, 74(4): 323-331.
107 WestS L, ScheidJ L, de SouzaM J. The effect of exercise and estrogen on osteoprotegerin in premenopausal women [J]. Bone, 2009, 44(1): 137-144.
108 BishopK A, CoyH M, NerenzR D, et al. Mouse Rank l expression is regulated in T cells by c-Fos through a cluster of distal regulatory enhancers designated the T cell control region [J]. J Biol Chem, 2011, 286(23): 20880-20891.

[1]	邵伟婷, 雷江华. 反应中断再定向干预孤独症谱系障碍儿童刻板语言的效果：Scoping综述[J]. 《中国康复理论与实践》, 2024, 30(1): 10-20.
[2]	周治宁, 周容, 肖燕文, 王博文, 吕娇娇, 刘宇. 多靶区经颅直流电刺激对健康成年人工作记忆-姿势控制双任务表现的影响[J]. 《中国康复理论与实践》, 2024, 30(1): 21-28.
[3]	王航宇, 葛可可, 范永红, 都丽露, 邹敏, 封磊. 基于ICD-11和ICF主动式音乐疗法改善认知障碍老年人认知功能的系统综述[J]. 《中国康复理论与实践》, 2024, 30(1): 36-43.
[4]	闻嘉宁, 金秋艳, 张琦, 李杰, 司琦. 认知参与型身体活动对发展儿童青少年执行功能的效果：基于ICF的系统综述[J]. 《中国康复理论与实践》, 2024, 30(1): 44-53.
[5]	葛可可, 范永红, 王航宇, 都丽露, 李长江, 邹敏. 失眠老年人正念干预健康效益的系统综述[J]. 《中国康复理论与实践》, 2024, 30(1): 54-60.
[6]	陈珺雯, 陈谦, 陈程, 李淑月, 刘玲玲, 吴存书, 龚翔, 鲁俊, 许光旭. 改良八段锦身体活动对脑卒中患者心肺功能、运动功能和日常生活活动能力的效果[J]. 《中国康复理论与实践》, 2024, 30(1): 74-80.
[7]	魏梦力, 钟亚平, 周易文, 桂辉贤, 关烨明, 于婷婷. 单侧前交叉韧带重建患者步行双侧下肢肌肉协同模式差异[J]. 《中国康复理论与实践》, 2024, 30(1): 95-104.
[8]	张婧雅, 邹敏, 孙宏伟, 孙昌隆, 朱峻同. 听障儿童青少年焦虑或抑郁情绪心理干预效果的系统综述[J]. 《中国康复理论与实践》, 2023, 29(9): 1004-1011.
[9]	王俊宇, 杨永, 袁逊, 谢婷, 庄洁. 高强度间歇训练对健康儿童青少年执行功能效果的系统综述[J]. 《中国康复理论与实践》, 2023, 29(9): 1012-1020.
[10]	魏晓微, 杨剑, 魏春艳. 特殊教育学校孤独症谱系障碍儿童参与适应性瑜伽活动的心理与行为效益的系统综述[J]. 《中国康复理论与实践》, 2023, 29(9): 1021-1028.
[11]	杨亚茹, 杨剑. 基于WHO-HPS架构学校身体活动相关健康服务及其健康效益：系统综述的系统综述[J]. 《中国康复理论与实践》, 2023, 29(9): 1040-1047.
[12]	史佳伟, 李凌宇, 杨浩杰, 王琴潞, 邹海欧. 预康复对全膝关节置换术后患者的有效性：系统综述的系统综述[J]. 《中国康复理论与实践》, 2023, 29(9): 1057-1064.
[13]	张冠聪, 黄秋晨, 顾蕊, 刘四海, 胡春英, 刘克敏. 不同神经肌肉训练方法对早期膝骨关节炎患者疼痛和运动功能效果的比较[J]. 《中国康复理论与实践》, 2023, 29(9): 1090-1097.
[14]	孙藤方, 任梦婷, 杨琳, 王耀霆, 王红雨, 闫兴洲. 高压氧治疗联合重复外周磁刺激干预脑卒中患者踝运动功能和平衡能力的效果[J]. 《中国康复理论与实践》, 2023, 29(8): 875-881.
[15]	王亚楠, 刘西花. 脑卒中偏瘫患者主观和客观平衡功能测量的相关性及预测效能[J]. 《中国康复理论与实践》, 2023, 29(8): 890-895.